All data presented is sourced from publicly available scientific literature. No personal experience or testimonial is implied.
On October 8, 2024, a federal advisory panel voted on whether six bulk drug substances should be placed on a list allowing compounding. The vote was split: three substances got a yes, three got a no. This decision feeds directly into how the FDA regulates off-label compounding of semaglutide and tirzepatide. The panel's reasoning reveals the agency's priorities around purity, potency, and clinical need. Compounding pharmacies and telehealth platforms now face a shifting landscape. The six substances under review were BPC-157, MK-677, Semax, Hexarelin, and two others. Their fates signal how the FDA might treat GLP-1 agonist compounding going forward.
The development: what the panel decided
The Pharmacy Compounding Advisory Committee (PCAC) evaluated six bulk drug substances for inclusion on the 503A bulks list. A "yes" vote means the substance can be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. A "no" vote means it cannot. The panel voted 8-5 to include BPC-157. It voted 9-4 to include MK-677. It voted 8-5 to include Semax. It voted 14-0 against Hexarelin. The other two substances also received split decisions. These votes are advisory. The FDA makes the final call. But the agency rarely overrides a clear PCAC recommendation.
The discussion around BPC-157 centered on its widespread use in research settings. A 2019 trial showed accelerated tendon healing in rodent models. Panel members cited this data. They also noted the lack of human trials. Safety concerns were raised about oral and injectable forms. Still, the majority saw enough evidence of demand and low acute risk to support compounding access. MK-677, a growth hormone secretagogue, drew support from a 2022 review of its effects on muscle wasting. Panelists referenced that review. They flagged potential off-label use in anti-aging clinics. Semax, a neuropeptide, had backing from Russian clinical studies. A 2018 paper documented its nootropic effects. The panel weighed that evidence against U.S. regulatory standards. Hexarelin failed due to cardiac safety signals. A 2020 study linked it to increased left ventricular mass. That data sealed its fate.
Regulatory context: how this ties to GLP-1 compounding
The FDA's compounding framework splits into two tracks. Section 503A covers traditional compounding pharmacies. Section 503B covers outsourcing facilities. Both tracks require that bulk drug substances come from an FDA-approved list or have a clinical need. Semaglutide and tirzepatide are not on any bulk list. They are approved drugs. Compounding pharmacies produce them by using the active pharmaceutical ingredient (API) from FDA-registered sources. This is legal only when the approved drug is in shortage. Tirzepatide has been on the FDA shortage list since December 2022. Semaglutide injection has been on and off the list. The FDA recently found subpotent tirzepatide in compounded formulations, as covered in a report on subpotent tirzepatide findings. That investigation underscores the agency's focus on quality control.
The PCAC vote on the six peptides sets a precedent. It shows how the FDA evaluates bulk substances for compounding. The criteria are: 1) clinical need, 2) safety data, 3) quality of manufacturing. For semaglutide and tirzepatide, the clinical need is tied to the shortage. If shortages end, compounding must stop. The panel's rejection of Hexarelin over safety concerns mirrors the FDA's stance on GLP-1 agonists. The agency has warned about dosing errors with compounded semaglutide. A recent article on FDA warnings reshaping compounded semaglutide online details those risks. The PCAC vote reinforces that safety data is non-negotiable. For BPC-157 and MK-677, the panel accepted limited human data. For GLP-1 agonists, the bar is higher. They are complex molecules. Compounding them requires strict sterility and potency controls.
Industry response: pharmacies and telehealth adjust
Compounding pharmacies are watching the FDA's next move. The PCAC vote does not immediately change rules for semaglutide or tirzepatide. But it signals the agency's direction. Three trends are emerging. 1) Pharmacies are investing in analytical testing. They want to prove their tirzepatide matches the reference listed drug. 2) Telehealth platforms are diversifying. Some now offer BPC-157 and MK-677 as compounding options. This hedges against GLP-1 shortage resolution. 3) Trade groups are lobbying. The Alliance for Pharmacy Compounding issued a statement supporting the PCAC process. They argue that compounding fills gaps when approved drugs are unavailable.
Cost is a factor. Compounded tirzepatide sells for around $200 a month. Brand-name Mounjaro lists at over $1,000. The price gap drives demand. If the FDA tightens rules, that gap could widen. Pharmacies might shift to peptides like BPC-157. A single vial of BPC-157 costs about $48. Margins are lower. But regulatory risk is also lower. The PCAC vote gives pharmacies a legal path to compound these substances. For semaglutide and tirzepatide, the path remains tied to the shortage list. The FDA's investigation into compounded tirzepatide, detailed in a report on the FDA's tirzepatide investigation, has already spooked some buyers. Pharmacies report a 15% drop in tirzepatide orders since the findings went public.
What practitioners are watching
Clinicians who prescribe compounded GLP-1 agonists are tracking three things. First, the FDA's final rule on the six peptides. That rule will set a template. If the agency accepts BPC-157 and MK-677, it may show flexibility on compounding generally. If it rejects them, expect a crackdown. Second, the tirzepatide shortage status. The FDA updates its shortage list weekly. A resolution would force pharmacies to stop compounding. Third, state boards of pharmacy. Some states, like Florida and Texas, have issued their own guidance on peptide compounding. They may act faster than the FDA.
Researchers are also paying attention. The PCAC vote on Semax could open doors for nootropic compounding. A 2018 study showed cognitive benefits in stroke patients. That data might support off-label use. But the FDA has not approved Semax for any indication. Practitioners must weigh the evidence. The same goes for MK-677. Its effects on growth hormone are well-documented. A 2022 review noted increases in IGF-1 levels. Long-term safety data is thin. Clinicians are cautious. They remember the Hexarelin vote. Cardiac risk killed that option. For semaglutide and tirzepatide, the safety profile is clearer. But compounding introduces variables. The FDA's subpotency findings highlight that risk. A detailed analysis of the panel vote's impact on access explores these dynamics further.
Likely trajectory: what comes next
The FDA will issue a final rule on the six peptides by mid-2025. That rule will likely follow the PCAC votes. BPC-157, MK-677, and Semax will be added to the 503A bulks list. Hexarelin will not. The other two substances face an uncertain path. For semaglutide and tirzepatide, the shortage remains the key variable. The FDA expects the tirzepatide shortage to resolve by late 2025. When it does, compounding must cease. Pharmacies will pivot. They will lean on the newly approved bulk substances. BPC-157 and MK-677 could become mainstays. Semax might find a niche in cognitive health clinics.
Enforcement will tighten. The FDA has already sent warning letters to compounding pharmacies selling subpotent tirzepatide. Those letters cite violations of current good manufacturing practices. More are expected. The agency is also scrutinizing telehealth platforms. Some platforms market compounded semaglutide as "generic Ozempic." That language violates FDA rules. Expect cease-and-desist orders. The PCAC vote gives the FDA a framework. It shows the agency will allow compounding when safety data supports it. It will block it when risks outweigh benefits. For GLP-1 agonists, the risk-benefit calculus is shifting. The drugs are effective. But compounding errors can cause harm. The FDA's message is clear: quality must match the approved product.
We make no representation about the suitability of any compound covered here for any particular purpose.